Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.

Andersen MA, Sotty F, Jensen PH, Badolo L, Jeggo R, Smith GP, Christensen KV.

eNeuro. 2019 Dec 19;6(6). pii: ENEURO.0453-18.2019. doi: 10.1523/ENEURO.0453-18.2019. Print 2019 Nov/Dec.

2.

Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation.

Andersen MA, Christensen KV, Badolo L, Smith GP, Jeggo R, Jensen PH, Andersen KJ, Sotty F.

Neurobiol Dis. 2018 Aug;116:13-27. doi: 10.1016/j.nbd.2018.04.011. Epub 2018 Apr 20.

PMID:
29680709
3.

PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats.

Andersen MA, Wegener KM, Larsen S, Badolo L, Smith GP, Jeggo R, Jensen PH, Sotty F, Christensen KV, Thougaard A.

Toxicology. 2018 Feb 15;395:15-22. doi: 10.1016/j.tox.2018.01.003. Epub 2018 Jan 4.

4.

Vendor-derived differences in injury-induced pain phenotype and pharmacology of Sprague-Dawley rats: Does it matter?

Kristensen PJ, Heegaard AM, Hestehave S, Jeggo RD, Bjerrum OJ, Munro G.

Eur J Pain. 2017 Apr;21(4):692-704. doi: 10.1002/ejp.973. Epub 2016 Nov 2.

PMID:
27805755
5.

α7-nAChR agonist enhances neural plasticity in the hippocampus via a GABAergic circuit.

Townsend M, Whyment A, Walczak JS, Jeggo R, van den Top M, Flood DG, Leventhal L, Patzke H, Koenig G.

J Neurophysiol. 2016 Dec 1;116(6):2663-2675. doi: 10.1152/jn.00243.2016. Epub 2016 Sep 21.

6.

Hippocampal 5-HT7 receptors signal phosphorylation of the GluA1 subunit to facilitate AMPA receptor mediated-neurotransmission in vitro and in vivo.

Andreetta F, Carboni L, Grafton G, Jeggo R, Whyment AD, van den Top M, Hoyer D, Spanswick D, Barnes NM.

Br J Pharmacol. 2016 May;173(9):1438-51. doi: 10.1111/bph.13432. Epub 2016 Mar 21.

7.

Lack of support for bexarotene as a treatment for Alzheimer's disease.

O'Hare E, Jeggo R, Kim EM, Barbour B, Walczak JS, Palmer P, Lyons T, Page D, Hanna D, Meara JR, Spanswick D, Guo JP, McGeer EG, McGeer PL, Hobson P.

Neuropharmacology. 2016 Jan;100:124-30. doi: 10.1016/j.neuropharm.2015.04.020. Epub 2015 May 27.

PMID:
26025659
8.

MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice.

Rammes G, Gravius A, Ruitenberg M, Wegener N, Chambon C, Sroka-Saidi K, Jeggo R, Staniaszek L, Spanswick D, O'Hare E, Palmer P, Kim EM, Bywalez W, Egger V, Parsons CG.

Neuropharmacology. 2015 May;92:170-82. doi: 10.1016/j.neuropharm.2014.12.037. Epub 2015 Jan 28.

PMID:
25637092
9.

In vivo electrophysiological recording techniques for the study of neuropathic pain in rodent models.

Zhao FY, Jeggo R, Wei H, Whyment A, Fang X, Spanswick D.

Curr Protoc Pharmacol. 2014 Sep 2;66:11.15.1-26. doi: 10.1002/0471141755.ph1115s66.

PMID:
25181009
10.

Electrophysiological Techniques for Studying Synaptic Activity In Vivo.

Jeggo R, Zhao FY, Spanswick D.

Curr Protoc Pharmacol. 2014 Mar 3;64:11.11.1-17. doi: 10.1002/0471141755.ph1111s64.

PMID:
26344209
11.

Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease.

O'Hare E, Scopes DI, Kim EM, Palmer P, Spanswick D, McMahon B, Amijee H, Nerou E, Treherne JM, Jeggo R.

Int J Neuropsychopharmacol. 2014 Jan;17(1):117-26. doi: 10.1017/S1461145713000886. Epub 2013 Oct 8.

12.

Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo.

Hopkins SC, Campbell UC, Heffernan ML, Spear KL, Jeggo RD, Spanswick DC, Varney MA, Large TH.

Pharmacol Res Perspect. 2013 Oct;1(1):e00007. doi: 10.1002/prp2.7. Epub 2013 Oct 1.

13.

Orally bioavailable small molecule drug protects memory in Alzheimer's disease models.

O'Hare E, Scopes DI, Kim EM, Palmer P, Jones M, Whyment AD, Spanswick D, Amijee H, Nerou E, McMahon B, Treherne JM, Jeggo R.

Neurobiol Aging. 2013 Apr;34(4):1116-25. doi: 10.1016/j.neurobiolaging.2012.10.016. Epub 2012 Nov 17.

PMID:
23164690
14.

The N-methylated peptide SEN304 powerfully inhibits Aβ(1-42) toxicity by perturbing oligomer formation.

Amijee H, Bate C, Williams A, Virdee J, Jeggo R, Spanswick D, Scopes DI, Treherne JM, Mazzitelli S, Chawner R, Eyers CE, Doig AJ.

Biochemistry. 2012 Oct 23;51(42):8338-52. doi: 10.1021/bi300415v. Epub 2012 Oct 12.

PMID:
23025847
15.

Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity.

Scopes DI, O'Hare E, Jeggo R, Whyment AD, Spanswick D, Kim EM, Gannon J, Amijee H, Treherne JM.

Br J Pharmacol. 2012 Sep;167(2):383-92. doi: 10.1111/j.1476-5381.2012.01973.x.

16.

Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576.

Bursi R, Erdemli G, Campbell R, Hutmacher MM, Kerbusch T, Spanswick D, Jeggo R, Nations KR, Dogterom P, Schipper J, Shahid M.

Psychopharmacology (Berl). 2011 Dec;218(4):713-24. doi: 10.1007/s00213-011-2365-6. Epub 2011 Jun 7.

PMID:
21647578
17.

Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.

Langmead CJ, Austin NE, Branch CL, Brown JT, Buchanan KA, Davies CH, Forbes IT, Fry VA, Hagan JJ, Herdon HJ, Jones GA, Jeggo R, Kew JN, Mazzali A, Melarange R, Patel N, Pardoe J, Randall AD, Roberts C, Roopun A, Starr KR, Teriakidis A, Wood MD, Whittington M, Wu Z, Watson J.

Br J Pharmacol. 2008 Jul;154(5):1104-15. doi: 10.1038/bjp.2008.152. Epub 2008 May 5.

18.
19.

The role of central 5-HT3 receptors in vagal reflex inputs to neurones in the nucleus tractus solitarius of anaesthetized rats.

Jeggo RD, Kellett DO, Wang Y, Ramage AG, Jordan D.

J Physiol. 2005 Aug 1;566(Pt 3):939-53. Epub 2005 May 19.

20.

Effect of pulmonary C-fibre afferent stimulation on cardiac vagal neurones in the nucleus ambiguus in anaesthetized cats.

Wang Y, Jones JF, Jeggo RD, de Burgh Daly M, Jordan D, Ramage AG.

J Physiol. 2000 Jul 1;526 Pt 1:157-65.

Supplemental Content

Support Center